已收盤 02-06 16:00:00 美东时间
+0.430
+2.87%
今日重点评级关注:Guggenheim:维持MBX Biosciences"买入"评级,目标价从77美元升至88美元;摩根士丹利:维持DraftKings"超配"评级,目标价从50美元升至53美元
01-20 10:26
UBS analyst Andre Salles downgrades Afya (NASDAQ:AFYA) from Buy to Neutral and lowers the price target from $18 to $16.
01-16 21:42
今日重点评级关注:HC Wainwright & Co.:维持奥麦罗制药"买入"评级,目标价从20美元升至40美元;HC Wainwright & Co.:维持Cullinan Therapeutics"买入"评级,目标价从26美元升至27美元
01-09 20:22
今日重点评级关注:Needham:维持Vaxcyte"买入"评级,目标价从90美元升至110美元;Citizens: 维持LGI Homes"跑赢大市"评级,目标价从85美元升至95美元
01-08 18:33
Top Wall Street analysts changed their outlook on these top names. For a comple...
01-07 21:04
JP Morgan analyst Marcelo Santos downgrades Afya (NASDAQ:AFYA) from Overweight to Neutral and lowers the price target from $24.5 to $22.
01-07 20:29
An update from Afya ( ($AFYA) ) is now available. On December 17, 2025, Afya Li...
2025-12-18 05:59
Afya (NASDAQ:AFYA) affirms FY2025 sales outlook from $626.675 million-$643.750 million to $626.675 million-$643.750 million.
2025-11-13 05:35
Afya (NASDAQ:AFYA) reported quarterly earnings of $0.38 per share which beat the analyst consensus estimate of $0.31 by 22.58 percent. This is a 18.75 percent increase over earnings of $0.32 per share from the same
2025-11-13 05:29